Home
Corporate
Operations
- R & D
- Project Portfolio
- Prioritized projects
  - Lipsovir
  - TMC435
  - MIV-701
  - HIV PI
  - HCV POL
  - KOL PI
  - Renin
  - BACE
  - Cathepsin K
  - Cathepsin S
- Polymerase inhibitor projects
  - Valomaciclovir
  - Alovudine
  - MIV-210
  - MIV-150
  - MIV-410
  - MIV-160
- Technologies
- Patents
IR & Media
Career and Contact
Search

Valomaciclovir (MIV-606)

Therapy Area
An NRTI addressing herpes zoster (shingles) and post-herpetic neuralgia (PHN) Also active against other herpes viruses.

Competitive Edge
Phase II results indicate reduction of shingles-related PHN more effectively than current therapy.

Licensee
Epiphany Biosciences

Last Modified: 05/09/2008